gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · FTREHealthcareMedical Labs

Fortrea Holdings Inc. Common Stock (FTRE)

$20.83−0.57%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$20.83▲ 114.74% in range
Nov 4, 2025Low $8.87 · High $25.88Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Fortrea Holdings closed at $20.83 on Nov 4, down 0.57%, 19.5% below its 52-week closing high. Volume of 1.4M shares was 0.68× its 20-day average (below normal).

Split-adjusted performance: +0.2% over one month, +33.2% over six months, +105.8% over one year.

In the quarter ended Sep 30, 2026, revenue was $691.50M, down 1.4% from a year earlier, with a net margin of 0.1%.

Short interest was 7.7M shares at the Oct 15 settlement, down 38.9% from the prior report (8.1% of float, 4.1 days to cover).

Market cap$2.01B96.5M shares
Revenue · quarter$691.5M−1.4% YoY
Diluted EPS$0.01—
P/E · TTM—P/S 0.8×
Net margin0.1%Gross 20.2%
Dividend yieldNone
52-week range8.87 – 25.88−19.5% from high
Volume1.4M0.68× 20-day avg
Volatility · 60d58.0%Annualised
Short % of float8.1%4.1 days to cover
Net cash-$834.7MCash $220.6M
Next earnings—Not scheduled
Split-adjusted performance
1W −19.5%1M +0.2%3M +17.8%6M +33.2%YTD +20.8%1Y +105.8%3Y −23.7%5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Medical Labs

Percentile among 24 companies (100 = best)

6-month momentum41
Revenue growth6
Net margin62
Value (low P/E)—
Size52

Industry medians: 6-month return +36.9%, revenue growth +25.0%, net margin −4.0%, P/E 32.4×.

Short interest

Details →
Shares short7.7M−38.9% vs prior
Days to cover4.1Settled Oct 15
% of float8.1%
Short vol. 10d57.7%of daily volume

Closest peers by size in Medical Labs

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
FTREFortrea Holdings$20.83−0.57%+33.2%−1.4%0.1%—$2.01B
PSNLPersonalis$15.79+0.25%+160.1%+30.0%−141.7%—$1.69BCompare
LMRILumexa Imaging Holdings$13.10+16.76%+27.4%—1.0%—$1.26BCompare
FRNMFreenome$11.30−1.48%————$1.21BCompare
CELCCelcuity$69.24−0.69%−50.3%———$3.39BCompare
CSTLCastle Biosciences$35.75+1.74%+44.4%+20.1%−2.0%—$1.09BCompare
VCYTVeracyte$52.52+4.43%+27.5%+15.5%17.0%36.9$4.22BCompare
CDNACareDx$85.86−2.95%+309.8%+39.3%13.8%35.1$4.51BCompare
BLLNBillionToOne$113.89+3.11%+39.9%—7.4%—$5.37BCompare

News about Fortrea Holdings

All news →
Fortrea Holdings Inc. (FTRE) Q3 Earnings and Revenues Surpass EstimatesZacks Investment Research · 6d ago▲ PositiveFortrea to Participate in Jefferies Global Healthcare ConferenceGlobeNewswire Inc. · Oct 27, 2026NeutralKolaborasi Fortrea dan Omico untuk Mendorong Pengembangan Obat Onkologi Berbasis BiomarkerGlobeNewswire Inc. · Oct 23, 2026▲ PositiveFortrea Holdings Inc. (FTRE) Earnings Expected to Grow: Should You Buy?Zacks Investment Research · Oct 22, 2026NeutralFortrea acquiert l’unité de pharmacologie clinique et les activités de laboratoire bioanalytique de Worldwide Clinical TrialsGlobeNewswire Inc. · Sep 3, 2026▲ Positive

Quick answers

What does Fortrea Holdings do?
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials.
What is FTRE's market cap?
$2.01B, based on the Nov 4 close of $20.83.
Does Fortrea Holdings pay a dividend?
No regular cash dividend has been paid in the last year.
How much of FTRE is sold short?
7.7M shares, 8.1% of float, as of Oct 15, 2026.
What sector is FTRE in?
Healthcare, in the Medical Labs industry.

About Fortrea Holdings

Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.

HQ: Durham, NC14,000 employeesListed Jun 16, 2023fortrea.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology